2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2427

Exosomes Derived from T Lymphocytes Enhance Expression of CXCL10 Induced By IFN-γin Rheumatoid Arthritis Synovial Fibroblasts Via Pattern Recognition Receptor, RIG-I
Abstract Number: 293

Expanded Therapeutic ACPA Utility for Different NET-Driven Human (Autoimmune) Diseases
Abstract Number: 118

Experiences and Perceptions of Patients with Rheumatoid Arthritis Participating in an Online Support Group: The Use of Social Media
Abstract Number: 2580

Exploiting Inhibition of PD1 Signaling in a Murine Model of Anti-SSA/Ro Associated Congenital Heart Block
Abstract Number: 418

Exploratory Analysis to Identify Factors Associated with Risk of Structural Progression, Defined As Change from Baseline
Abstract Number: 2597

Explorer Study: Rituximab Use in Systemic Lupus Erythematosus, a New Look on Old Data
Abstract Number: 1197

Exploring Determinants Predicting Response to Intra-Articular Hyaluronic Acid Treatment in Symptomatic Knee Osteoarthritis
Abstract Number: 2323

Exploring HLA-DRB1 Risk Alleles in Non-Hispanic African American Children with Juvenile Idiopathic Arthritis and Chronic Anterior Uveitis
Abstract Number: 2653

Exposure to a Periodontal Pathogen Aggregatibacter Actinomycetemcomitans Is Associated with Increased SLE Severity
Abstract Number: 2104

Exposure to Fine Particle Air Pollution and Anti-Nuclear Antibodies (ANA) in a Large Population-Based Sample
Abstract Number: 125

Exposure to Passive Smoking and RA Risk; Results from a Swedish Case-Control Study
Abstract Number: 505

Exposure-Response Analyses of the Effect of Upadacitinib on ACR Responses in the Phase 2b Rheumatoid Arthritis Trials in Patients with Inadequate Response to Methotrexate or to Anti-Tumor Necrosis Factor Therapy
Abstract Number: 2586

Exposure-Response Modelling and Exposure-Safety Modelling Analyses in Two Phase II Studies of Atacicept in SLE
Abstract Number: 2336

Expression of Myxovirus-Resistance Protein a: A Possible Marker of Muscular Disease Activity in Juvenile Dermatomyositis
Abstract Number: 2339

Expression of Type I and Type II Interferons Is Increased in Muscle Biopsies of Juvenile Dermatomyositis Patients and Related to Clinical and Histological Features

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].